bpc-157 tight junction intestinal permeability as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Bowel adhesion and therapy with

KPV studies have focused specifically on mucosal inflammation models, showing reduced inflammatory markers in intestinal tissue

Mechanism of Action (MOA): Inhibit the DPP-4 enzyme, preventing the breakdown of endogenous GLP-1, leading to: Glucose-dependent insulin secretion Glucose-dependent glucagon secretion Efficacy: HbA1c reduction: 0.6%0.8% Primarily reduces postprandial glucose Common Dosing: Sitagliptin (Januvia): 100 mg once daily (dose adjustment required in renal impairment) Saxagliptin (Onglyza): 5 mg once daily ( dose in renal impairment) Linagliptin (Tradjenta): 5 mg once daily (no renal or hepatic dose adjustment) Alogliptin (Nesina): 25 mg once daily ( dose in renal impairment) Adverse Effects: Generally placebo-like URTI, headache, mild GI upset Advantages: Weight neutral Suitable for patients with renal impairment (with dose adjustment) Well-tolerated Possible -cellsparing effect Disadvantages: Risk of acute pancreatitis Joint pain Saxagliptin & alogliptin: potential risk of heart failure Precautions: History of pancreatitis Not recommended in DKA Not indicated in Type 1 Diabetes Monitor for heart failure (saxagliptin, alogliptin) #DPP4Inhibitors #Type2Diabetes #ClinicalPharmacy #Pharmacology #MedicationSafety #DiabetesCare #Endocrinology #PharmacyEducation #HealthcareProfessionals To view or add a comment, sign in 3,206 followers

B12 absorption starts in the stomach with something called intrinsic factor (1) and eventually makes its way to the small intestine where it is fully absorbed

Ready To Experience The Benefits Of IV Therapy & Cryotherapy

Lactation: Risk Summary: Zinc is present in human milk